22 Sep, 2026 Baseline Characteristics for cAPPricorn-1 Phase 2 Study Presented at the International Cerebral Amyloid Angiopathy (ICAA) Conference
body
A review of the baseline characteristics of participants enrolled in the cAPPricorn-1 study, an ongoing phase 2, double-blind, placebo-controlled study of mivelsiran in individuals with cerebral amyloid angiopathy (CAA) were presented at the International CAA (ICAA) Conference in Banff, Canada. A review of ethnic and racial differences in the distribution of cerebral microbleeds among patients with lobar intracerebral hemorrhage enrolled in the Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study was also presented.
